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Background
While the induction of neutralizing antibodies remains a
cornerstone of HIV vaccine development, the success of
the Thai trail and evidence from non-human primate
(NHP) studies has indicated that non-neutralizing antibo-
dies may provide protection from infection. These non-
neutralizing antibodies can act as molecular beacons to
recruit innate immune cells to recognize infected CD4T
cells or free virus as pathogenic. The ability of an antibody
to efficiently recruit innate immune cells depends on com-
plex interactions between the pathogenic target, the anti-
body, and an effector cell.
Methods
Here we present a quantitative model of natural killer cell
mediated antibody dependent cellular cytotoxicity
(ADCC), and examine the impact of core fucosylation,
FcgR3a expression/occupancy, serum IgG competition
and mutations in the Fc binding domain.
Results
The results indicate that FcgR3a site occupancy can pre-
dict the percentage of cells killed on an ADCC dose
response curve. In addition, it appears ADCC is initiated
past a threshold of FgR3a site occupancy on the natural
killer cell.
Conclusion
This provides key insight into the mechanism of the
innate immune response and provides powerful evidence
that the effector function of antibodies should be a key
consideration in the development of HIV vaccines.
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